Verdel Instruments has developed the first benchtop instrument with two dimensional mass spectrometry (2DMS) capability. It delivers rapid high quality structural analysis and sequencing of every component in a complex mixture, making pharmaceutical research and food safety testing more accurate, more efficient, and up to 10 times quicker than current mass spectrometry approaches. Verdel’s instrument is compatible with any mass spectrometer that uses linear ion trap technology.
Currently, mass spectrometers cannot analyse more than one component at a time, which means the user scientist must accept a loss of information about impurities or parts of the entire structure. 2DMS solves this problem by providing a way to fragment many molecules simultaneously whilst retaining the knowledge of which fragment comes from which molecule. It uses electric pulses to manipulate ions in a linear ion trap before fragmentation to enable parallel acquisition of mass spectra, which operates in combination with UV laser-based fragmentation and a fast mass analyser such as a time-of-flight.
Verdel has been working on 2DMS for about 8 years using an expensive, high-resolution mass spectrometer, and have now solved some key issues to enable its broader uptake as a benchtop instrument.
They have done analysis of small pharmaceutical and agrichemical molecules, sequenced multiple complex protein or peptides, complex polymer distributions, monoclonal antibodies, proteomics samples, and whole proteins, and are currently working to expand the capabilities into environmental testing, petroleum analysis, food-safety, and clinical analysis. They are now looking to work with pharmaceutical companies to analyse samples and test the technology.
In 2019, Verdel was awarded funding by Innovate UK and raised seed investment from Longwall Ventures. This was followed in 2020 with a funding round which raised £2m including £1m from the government backed Futures Fund and a further investment from Longwall Ventures.